

Happy  Thanksgiving

In A Nutshell
November 2020
Therapy Status

It has been two years since I did an update on the various MS therapies. I thought it would be interesting to see what progress has been made over that time.

Changes to injectables: Kesimpta was added and Zinbryta was taken off the market.

Changes to oral medications: New additions are Mavenclad, Mayzent, Vumerity, Zeposia. Also the FDA approved a generic version of Tecfidera.

Changes to infusions: None

Just For Fun

The following is the US Food and Drug Administration (FDA) approved disease modifying therapies for MS:

(how many have you tried?)

- o [Avonex®](#) (interferon beta-1a)
- o [Betaseron®](#) (interferon beta-1b)
- o [Copaxone®](#) (glatiramer acetate)
- o [Extavia®](#) (interferon beta-1b)
- o [Glatiramer Acetate Injection](#) (glatiramer acetate -generic equivalent of Copaxone 20 mg and 40 mg doses)
- o [Glatopa®](#) (glatiramer acetate - generic equivalent of Copaxone 20mg and 40mg doses)

- [Kesimpta®](#) (ofatumumab)
- [Plegridy®](#) (peginterferon beta-1a)
- [Rebif®](#) (interferon beta-1a)
- Oral medications
 - [Aubagio®](#) (teriflunomide)
 - [Bafiertam™](#) (monomethyl fumarate)
 - [Dimethyl Fumarate](#) (dimethyl fumarate - generic equivalent of Tecfidera)
 - [Gilenya®](#) (fingolimod)
 - [Mavenclad](#) (cladribine)
 - [Mayzent](#) (siponimod)
 - [Vumerity](#) (diroximel fumarate)
 - [Zeposia](#) (ozanimod)

Infused Medications

[Lemtrada®](#)
[Novantrone®](#)
[Ocrevus](#)
[Tysabri®](#)

<https://www.nationalmssociety.org/Treating-MS/Medications>